LONDON: GlaxoSmithKline Plc GSK.L has agreed a deal worth more than $350 million (209 million pounds) with British biotech company Adaptimmune to develop cancer drugs based on novel cell-based therapies.
Adaptimmune said on Monday it would collaborate with GSK on its lead clinical program, which it said had already generated encouraging results in multiple myeloma, melanoma, sarcoma and ovarian cancer in trials in the United States.
According to a Reuters report, the privately-owned company said it could receive payments in excess of $350 million over the next seven years from the tie-up, subject to development goals being met, and significant development and commercialization payments in subsequent years.
Adaptimmune said it would also receive sales royalties, ranging from single to double digits on net sales, on any products that reach market.
The company’s cancer therapies work by re-engineering the patient’s own t-cells, a type of white blood cell, to target and destroy cancerous or infected cells.
Dear TNT Reader,
At The News Tribe, our mission is to bring you free, independent, and unbiased news and content that keeps you informed and empowered. We are committed to upholding the highest standards of journalism, as we understand that we are a platform for truth.
Apart from independent global news coverage, we also commit our unique focus on the Muslim world. In an age marked by the troubling rise of Islamophobia and widespread misrepresentation of Muslims in Western media, we strive to provide accurate and fair coverage.
But to continue doing so, we need your support. Even a small donation of 1$ can make a big difference. Your contribution will help us maintain the quality of our news and counteract the negative narratives that are so prevalent.
Please consider donating today to ensure we can keep delivering the news that matters. Together, we can make a positive impact on the world, and work towards a more inclusive, informed global society.
Donate Monthly Subscription Annual Subscription